Positive for BOT, page-138

Interesting Article

http://fortune.com/2018/04/19/marijuana-epilepsy-fda-gw-pharmaceuticals/

An FDA panel on Thursday enthusiastically endorsed Epidiolex during an advisory committee meeting. In a unanimous 13-0 vote, the outside experts said GW Pharma’s experimental cannabis therapy’s benefits outweighed its risks in treating rare forms of epilepsy like Lenox-Gastaut Syndrome (LGS) and Dravet syndrome (DS), lining up a near-certain FDA approval between now and the end of June. The FDA isn’t bound to follow its advisers’ recommendations—but it almost always does, especially when the recommendation is so lopsided.